Request Demo
Recent blog posts
Latest Hotspot
8 min read
NCT07476001 Testosterone Cypionate Metastatic castration-resistant prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07476001 clinical trial report covering Testosterone Cypionate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07475806 Enfortumab Vedotin-ejfv Muscle Invasive Bladder Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07475806 clinical trial report covering Enfortumab Vedotin-ejfv, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07477366 Nogapendekin alfa inbakicept-pmln Refractory Indolent Non-Hodgkin Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07477366 clinical trial report covering Nogapendekin alfa inbakicept-pmln, Phase 2, endpoints, sponsor, geography, readout timing and development white
Latest Hotspot
8 min read
NCT07477457 Trametinib dimethyl sulfoxide Neoplasm Metastasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07477457 clinical trial report covering Trametinib dimethyl sulfoxide, Phase 2, endpoints, sponsor, geography, readout timing and development white spac
Latest Hotspot
8 min read
ChiCTR2600120556 GBI268 Pain, Postoperative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
ChiCTR2600120556 clinical trial report covering GBI268, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07476677 Darolutamide Localized Prostate Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07476677 clinical trial report covering Darolutamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07477795 Secukinumab Takayasu Arteritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07477795 clinical trial report covering Secukinumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
KCT0011734 Everolimus Vascular Tissue Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
KCT0011734 clinical trial report covering Everolimus, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07477548 Everolimus Port-Wine Stain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07477548 clinical trial report covering Everolimus, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07478744 SYT-510 Generalized anxiety disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07478744 clinical trial report covering SYT-510, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07477782 Fecal microbiota transplantation(Assistance Publique des Hôpitaux de Paris) Cholangitis, Sclerosing Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07477782 clinical trial report covering Fecal microbiota transplantation(Assistance Publique des Hôpitaux de Paris), Phase 2, endpoints, sponsor, geogra
Latest Hotspot
8 min read
NCT07480863 Zuberitamab Marginal Zone B-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07480863 clinical trial report covering Zuberitamab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.